Neurochemical brain imaging investigations of schizophrenia

[1]  A. Carlsson,et al.  EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.

[2]  Godfrey D Pearlson,et al.  Structural brain imaging in schizophrenia: a selective review , 1999, Biological Psychiatry.

[3]  M. Laruelle,et al.  Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.

[4]  P. Williamson,et al.  A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls , 1999, Biological Psychiatry.

[5]  J. Hietala,et al.  Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia , 1999, Schizophrenia Research.

[6]  J A Frank,et al.  Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. , 1998, The American journal of psychiatry.

[7]  M. Laruelle.  Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[8]  Kevin T. Hansen,et al.  Dopamine D2 densities and the schizophrenic brain , 1998, Schizophrenia Research.

[9]  Stephen Ashwal,et al.  Proton Magnetic Resonance Spectroscopy: An Emerging Technology in Pediatric Neurology Research , 1998, Pediatric Research.

[10]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[11]  D. Brooks,et al.  Evidence for striatal dopamine release during a video game , 1998, Nature.

[12]  Marie-Laure Paillère-Martinot,et al.  No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET , 1998, Schizophrenia Research.

[13]  M Laruelle,et al.  D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene , 1998, Molecular Psychiatry.

[14]  J. Callicott,et al.  The relationship between prefrontal neuronal integrity and striatal amphetamine-induced dopamine activity in patients with schizophrenia , 1998, NeuroImage.

[15]  Alessandro Bertolino,et al.  Regionally Specific Neuronal Pathology in Untreated Patients with Schizophrenia: A Proton Magnetic Resonance Spectroscopic Imaging Study , 1998, Biological Psychiatry.

[16]  G. Fein,et al.  Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy , 1998, Biological Psychiatry.

[17]  H. Wikström,et al.  [carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo , 1998, European Journal of Nuclear Medicine.

[18]  J A Frank,et al.  Altered development of prefrontal neurons in rhesus monkeys with neonatal mesial temporo-limbic lesions: a proton magnetic resonance spectroscopic imaging study. , 1997, Cerebral cortex.

[19]  P. Goldman-Rakic,et al.  Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. , 1997, The Journal of pharmacology and experimental therapeutics.

[20]  J. Pierri,et al.  Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: Preliminary studies , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  R W Neufeld,et al.  Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. , 1997, Archives of general psychiatry.

[22]  J. Joyce,et al.  Alterations in the cortical serotonergic system in schizophrenia: A postmortem study , 1997, Biological Psychiatry.

[23]  Marc Laruelle,et al.  Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.

[24]  R. Conley,et al.  Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects , 1997, Psychiatry Research.

[25]  J. Joyce,et al.  Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. , 1997, Archives of general psychiatry.

[26]  R. Gonzalez,et al.  Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Goldman-Rakic,et al.  Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. , 1997, The Journal of pharmacology and experimental therapeutics.

[28]  R G Shulman,et al.  In vivo 13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Pearlson,et al.  Quantification of Neuroreceptors in the Living Human Brain: IV. Effect of Aging and Elevations of D2-Like Receptors in Schizophrenia and Bipolar Illness , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  C. Meltzer,et al.  Quantification of Neuroreceptors in the Living Human Brain: III. D2-Like Dopamine Receptors: Theory, Validation, and Changes during Normal Aging , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  M. Iyo,et al.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.

[33]  C. Crouzel,et al.  Presynaptic dopaminergic function in the striatum of schizophrenic patients , 1997, Schizophrenia Research.

[34]  J. Nobrega,et al.  Dopamine D2‐like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline , 1997, Synapse.

[35]  P B Hoffer,et al.  Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.

[36]  J. Hietala,et al.  Dopamine in schizophrenia. , 1996, Annals of medicine.

[37]  G Tedeschi,et al.  Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. , 1996, The American journal of psychiatry.

[38]  Paul J. Harrison,et al.  5-HT1A and 5-HT2A Receptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia , 1996, Neuropsychopharmacology.

[39]  P. Seeman,et al.  Dopamine D2 receptor dimers and receptor-blocking peptides. , 1996, Biochemical and biophysical research communications.

[40]  B. Dean,et al.  Decreased frontal cortical serotonin2A receptors in schizophrenia , 1996, Schizophrenia Research.

[41]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Pearlson,et al.  Striatal dopamine D2 receptor quantification and superior temporal gyrus: Volume determination in 14 chronic schizophrenic subjects , 1996, Psychiatry Research: Neuroimaging.

[43]  J. Mukherjee,et al.  18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors. , 1996, Life sciences.

[44]  Jullie W Pan,et al.  Quantitative 1H spectroscopic imaging of human brain at 4.1 T using image segmentation , 1996, Magnetic resonance in medicine.

[45]  Christer Halldin,et al.  Autoradiographic localization of extrastriatal D2‐dopamine receptors in the human brain using [125I]epidepride , 1996, Synapse.

[46]  J. Deakin,et al.  Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia , 1996, Biological Psychiatry.

[47]  E. Jerning,et al.  Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites. , 1996, European journal of pharmacology.

[48]  P A Sargent,et al.  Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. , 1996, European journal of pharmacology.

[49]  S. Kapur,et al.  Serotonin-dopamine interaction and its relevance to schizophrenia. , 1996, The American journal of psychiatry.

[50]  P. Renshaw,et al.  Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls , 1996, Schizophrenia Research.

[51]  R. Mark Wightman,et al.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.

[52]  H. Meltzer,et al.  Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia , 1996, Brain Research.

[53]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[54]  Toshiro Fujimoto,et al.  Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report , 1995, Psychiatry Research: Neuroimaging.

[55]  Karl J. Friston,et al.  Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia , 1995, Nature.

[56]  G J Barker,et al.  Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia , 1995, Psychological Medicine.

[57]  P. Matthews,et al.  Reversible decreases in N‐acetylaspartate after acute brain injury , 1995, Magnetic resonance in medicine.

[58]  J. Hietala,et al.  Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.

[59]  J. Kleinman,et al.  Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. , 1995, Archives of general psychiatry.

[60]  P. Goldman-Rakic,et al.  Modulation of memory fields by dopamine Dl receptors in prefrontal cortex , 1995, Nature.

[61]  G. Fein,et al.  Abnormal frontal lobe phosphorous metabolism in bipolar disorder. , 1995, The American journal of psychiatry.

[62]  D. Sulzer,et al.  Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[63]  P. Williamson,et al.  An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. , 1995, Archives of general psychiatry.

[64]  M. K. Das,et al.  Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. , 1995, Nuclear medicine and biology.

[65]  J. Krystal,et al.  Spect imaging of the benzodiazepine receptor in schizophrenics and healthy subjects , 1995, Schizophrenia Research.

[66]  P. Renshaw,et al.  Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. , 1995, The American journal of psychiatry.

[67]  John P. Stack,et al.  1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: Clinical, neurodevelopmental, and cognitive correlates , 1994, Biological Psychiatry.

[68]  J. Kleinman,et al.  Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients , 1994, Biological Psychiatry.

[69]  Alan C. Evans,et al.  Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[70]  P Schmalbrock,et al.  Proton Magnetic Resonance Spectroscopy (1H MRS) of the Hippocampal Formation in Schizophrenia: A Pilot Study , 1994, British Journal of Psychiatry.

[71]  O. Pryds,et al.  Metabolite concentrations in the developing brain estimated with proton MR spectroscopy , 1994, Journal of magnetic resonance imaging : JMRI.

[72]  P. Goldman-Rakic,et al.  A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[73]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[74]  V. Lehtinen,et al.  Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. , 1994, Archives of general psychiatry.

[75]  R. Kerwin.  The New Atypical Antipsychotics , 1994, British Journal of Psychiatry.

[76]  R. Murray,et al.  D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients , 1994, British Journal of Psychiatry.

[77]  Alan A. Wilson,et al.  Dopamine D2 receptor density estimates in schizophrenia: A positron emission tomography study with11C-N-methylspiperone , 1993, Psychiatry Research.

[78]  R. Kahn,et al.  Serotonin receptor responsivity in schizophrenia , 1993, International clinical psychopharmacology.

[79]  R. G. Manning,et al.  Evaluation of 5‐[18F]Fluoropropylepidepride as a potential pet radioligand for imaging dopamine D2 receptors , 1993, Synapse.

[80]  J. Kleinman,et al.  Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. , 1993, Archives of general psychiatry.

[81]  P. Seeman,et al.  Dopamine D4 receptors elevated in schizophrenia , 1993, Nature.

[82]  D. Weinberger,et al.  Postpubertal Emergence of Hyperresponsiveness to Stress and to Amphetamine after Neonatal Excitotoxic Hippocampal Damage: A Potential Animal Model of Schizophrenia , 1993, Neuropsychopharmacology.

[83]  R. Mattson,et al.  Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[84]  J. Kleinman,et al.  Serotonin Uptake Sites and Serotonin Receptors Are Altered in the Limbic System of Schizophrenics , 1993, Neuropsychopharmacology.

[85]  Robert M. Kessler,et al.  Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride , 1993, Brain Research.

[86]  P. Williamson,et al.  The study of schizophrenia via in vivo 31P and 1H MRS , 1993, Schizophrenia Research.

[87]  D. Gadian,et al.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[88]  T. Asakura,et al.  Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging , 1992, Acta psychiatrica Scandinavica.

[89]  J R Votaw,et al.  Visualization of extrastriatal dopamine D2 receptors in the human brain. , 1992, European journal of pharmacology.

[90]  R. Sunahara,et al.  The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. , 1992, European journal of pharmacology.

[91]  G. Sedvall.  The current status of PET scanning with respect to schizophrenia. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[92]  G. Fein,et al.  31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia , 1992, Biological Psychiatry.

[93]  J. Sangiovanni,et al.  Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[94]  Marc Laruelle,et al.  Amphetamine‐stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates , 1992, Synapse.

[95]  A. Grace.  Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia , 1991, Neuroscience.

[96]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[97]  R. G. Manning,et al.  High affinity dopamine D2 receptor radioligands. 1. Regional rat brain distribution of iodinated benzamides. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[98]  J. Waddington,et al.  Initial investigation of the left temporoparietal region in schizophrenia by 31P magnetic resonance spectroscopy , 1991, Biological Psychiatry.

[99]  M. Keshavan,et al.  Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. , 1991, Archives of general psychiatry.

[100]  K. Neve,et al.  Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain. , 1991, The Journal of pharmacology and experimental therapeutics.

[101]  J S Fowler,et al.  Amphetamine induced decreases in (18F)‐N‐methylspiroperidol binding in the baboon brain using positron emission tomography (PET) , 1991, Synapse.

[102]  P. Goldman-Rakic,et al.  D1 dopamine receptors in prefrontal cortex: involvement in working memory , 1991, Science.

[103]  Svante B. Ross,et al.  Synaptic Concentration of Dopamine in the Mouse Striatum in Relationship to the Kinetic Properties of the Dopamine Receptors and Uptake Mechanism , 1991, Journal of neurochemistry.

[104]  P. Seeman,et al.  Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride. , 1990, Archives of general psychiatry.

[105]  M. Kuhar,et al.  Methods in Neurotransmitter Receptor Analysis , 1990 .

[106]  P M Matthews,et al.  Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease , 1990, Magnetic resonance in medicine.

[107]  S. Stone-Elander,et al.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.

[108]  T. Bottiglieri,et al.  MULTIPLE SCLEROSIS AND MACROCYTOSIS , 1989, The Lancet.

[109]  G. Reynolds,et al.  Beyond the Dopamine Hypothesis , 1989, British Journal of Psychiatry.

[110]  P S Goldman-Rakic,et al.  Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[111]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[112]  N. Mataga,et al.  Neurotransmitters, receptors and neuropeptides in post‐mortem brains of chronic schizophrenic patients , 1988, Acta psychiatrica Scandinavica.

[113]  P Riederer,et al.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[114]  D. Weinberger.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[115]  C. Tanaka,et al.  [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. , 1987, Life sciences.

[116]  G. Pearlson,et al.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. , 1986, Science.

[117]  T. Kuno,et al.  Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics , 1986, Biological Psychiatry.

[118]  G. Reynolds,et al.  [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. , 1985, European journal of pharmacology.

[119]  T. Crow,et al.  Tritiated LSD binding in frontal cortex in schizophrenia. , 1981, Archives of general psychiatry.

[120]  H. H. Kornhuber,et al.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.

[121]  L. Iversen,et al.  Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects , 1980, Journal of the Neurological Sciences.

[122]  C. Carter,et al.  Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats , 1980, Nature.

[123]  T. Crow,et al.  Molecular pathology of schizophrenia: more than one disease process? , 1980, British medical journal.

[124]  S. Snyder,et al.  Neurotransmitter receptors in frontal cortex of schizophrenics. , 1979, Archives of general psychiatry.

[125]  Shirley Hansen,et al.  γ-AMINOBUTYRIC-ACID DEFICIENCY IN BRAIN OF SCHIZOPHRENIC PATIENTS , 1979, The Lancet.

[126]  P. Seeman,et al.  Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains , 1978, Nature.

[127]  J. Hyttel,et al.  Effects of neuroleptics on 3H-haloperidol and 3H-cis(Z)-flupenthixol binding and on adenylate cyclase activity in vitro. , 1978, Life sciences.

[128]  T. Crow,et al.  Dopaminergic mechanisms in schizophrenia: the antipsychotic effect and the disease process. , 1978, Life sciences.

[129]  M. Poulter,et al.  INCREASED DOPAMINE-RECEPTOR SENSITIVITY IN SCHIZOPHRENIA , 1978, The Lancet.

[130]  L. Iversen,et al.  INCREASED BRAIN DOPAMINE AND REDUCED GLUTAMIC ACID DECARBOXYLASE AND CHOLINE ACETYL TRANSFERASE ACTIVITY IN SCHIZOPHRENIA AND RELATED PSYCHOSES , 1977, The Lancet.

[131]  S. Snyder,et al.  Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. , 1977, Science.

[132]  S H Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.

[133]  P. Seeman,et al.  Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. , 1975, Science.

[134]  A. Sjoerdsma,et al.  Metabolism of alpha-methyltyrosine in man: relationship to its potency as an inhibitor of catecholamine biosynthesis. , 1968, The Journal of clinical investigation.

[135]  S. Kapur,et al.  Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. , 1999, The American journal of psychiatry.

[136]  Albert Gjedde,et al.  Quantification of Extracellular Dopamine Release in Schizophrenia and Cocaine Use by Means of TREMBLE , 1998 .

[137]  A. Gjedde,et al.  Quantitative functional brain imaging with positron emission tomography , 1998 .

[138]  R. Kerwin,et al.  Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. , 1997, The American journal of psychiatry.

[139]  G. Aghajanian,et al.  The role of serotonin in the pathophysiology and treatment of schizophrenia. , 1997, The Journal of neuropsychiatry and clinical neurosciences.

[140]  N. Yamaguchi,et al.  Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. , 1995 .

[141]  A Pfefferbaum,et al.  Structural brain imaging in schizophrenia. , 1995, Clinical neuroscience.

[142]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[143]  R. G. Manning,et al.  High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. , 1991, Life sciences.

[144]  P. Seeman,et al.  Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.

[145]  N. Andreasen,et al.  Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. , 1988, Schizophrenia bulletin.

[146]  R. Kahn,et al.  The role of serotonin in schizophrenia. , 1988, Schizophrenia bulletin.

[147]  P. Seeman,et al.  Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.

[148]  Philip Seeman,et al.  Human brain dopamine receptors in children and aging adults , 1987, Synapse.

[149]  L. Iversen,et al.  Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. , 1983, Journal of neural transmission. Supplementum.

[150]  K. Taeuber,et al.  Pharmacodynamic comparison of the acute effects of nomifensine, amphetamine and placebo in healthy volunteers. , 1979, International journal of clinical pharmacology and biopharmacy.

[151]  L. Iversen.  Dopaminergic mechanisms in schizophrenia. , 1977, Proceedings of the Royal Society of Medicine.

[152]  A. Sjoerdsma,et al.  BLOCKADE OF ENDOGENOUS NOREPINEPHRINE SYNTHESIS BY ALPHA-METHYL-TYROSINE, AN INHIBITOR OF TYROSINE HYDROXYLASE. , 1965, The Journal of pharmacology and experimental therapeutics.